Cost-effectiveness of enfortumab vedotin plus pembrolizumab as a first-line treatment of locally advanced or metastatic urothelial carcinoma in the United States
EV+Pem is cost-effective compared to platinum-based regimens for the treatment of previously untreated la/mUC from a US third party payer perspective at a willingness-to-pay threshold of $200,000/QALY.
Authors
- Aram Babcock (ORCID: https://orcid.org/0000-0003-0372-834X)
- Yang Meng (ORCID: https://orcid.org/0000-0003-1866-537X)
- Abhi Bavle
- Ronac Mamtani (ORCID: https://orcid.org/0000-0002-8267-5356)
- Yizhen Lai
- Shujing Zhang (ORCID: https://orcid.org/0000-0001-8956-1725)
- Mounir Aout
- Haojie Li (ORCID: https://orcid.org/0000-0001-6233-8603)
- Sarah Brand-Wiita
- Spencer Notinger
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Bard College Berlin (DE)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- University of Pennsylvania (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1080/13696998.2025.2567190
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00